We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 18, 2022

Talazoparib Monotherapy in BRCA1/2 Wild-Type HER2− Breast Cancer With a Mutation in Other Homologous Recombination Genes

Nature Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Nature Cancer
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Nat Cancer 2022 Oct 01;3(10)1181-1191, JJ Gruber, A Afghahi, K Timms, A DeWees, W Gross, VN Aushev, HT Wu, M Balcioglu, H Sethi, D Scott, J Foran, A McMillan, JM Ford, ML Telli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading